Works matching IS 27201015 AND DT 2021 AND VI 33 AND IP 2
Results: 5
The use of midostaurin in aggressive systemic mastocytosis (ASM) with the c-KIT D816V mutation within The Emergency Access to Drug Technologies Programme.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 84, doi. 10.5603/Hcp.2021.0011
- By:
- Publication type:
- Article
Effective midostaurin treatment in a patient with aggressive systemic mastocytosis.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 72, doi. 10.5603/Hcp.2021.0012
- By:
- Publication type:
- Article
The use of midostaurin in the treatment of advanced systemic mastocytosis.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 77, doi. 10.5603/Hcp.2021.0010
- By:
- Publication type:
- Article
Polish Experts' Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 67, doi. 10.5603/HCP.2021.0008
- By:
- Publication type:
- Article
Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2021.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 37, doi. 10.5603/HcP.2021.0001
- By:
- Publication type:
- Article